OPDP has seen a major drop in enforcement letters, culminating in a record low of just five warning and untitled letters sent to Orexigen Therapeutics, Cipher Pharmaceuticals, Magna Pharmaceuticals, Avanthi and the University of California Los Angeles in 2017. While OPDP has issued two other untitled letters so far this year, it has not issued any warning letters to drugmakers over advertising and promotion related issues.
Cipher Pharmaceuticals and Cardiome Pharma Announce Strategic Transaction for Canadian Business Portfolio of Cardiome
Cipher Pharmaceuticals Acquires Exclusive Canadian Rights to FDA-Approved TRULANCE® from Synergy Pharmaceuticals
As the end of the year nears, the pharma industry can usually look back at FDA enforcement letters for insight into the agency's thinking and guidance on marketing communications. But this year, there’s not much to review.
Previously, Mr. Watters held the position of Vice-President of Sales at GlaxoSmithKline, where he led a commercial organization of 300 sales and operations professionals delivering annual revenue of $700 million. As a key member of the executive team of Biovail Pharmaceuticals Canada, he served as Vice-President, Marketing providing leadership in new product launches, commercial assessment and business development. Most recently, Mr. Watters held the position of Senior Vice President, Marketing with Goba Sports Group, where he was responsible for global marketing, new product development, business development, and corporate strategy.
Cipher Pharmaceuticals (DND.TO), announced that Robert Tessarolo will take on the roles of president and chief executive officer effective April 17, 2017. In addition, at the company’s annual general meeting in May, he will be nominated to the board of directors.